Consano Bio
Consano Bio is a clinical-stage biotech company developing an allogeneic multi-protein biologic therapeutic intended to treat painful orthopedic conditions, with a lead indication in chronic lumbosacral radiculopathy (LSR). The company develops donor-derived plasma and platelet protein formulations, a manufacturing process for scalable drug-substance production and single-dose vial drug-product filling, and plans an IND submission and Phase 1 study.
Industries
Nr. of Employees
small (1-50)
Patents
Products
Allogeneic multi-protein therapeutic (C-1101)
A donor-derived multi-protein biologic formulation composed of supraphysiologic concentrations of plasma- and platelet-derived cytokines, matrix proteins, and growth factors intended for local delivery to accelerate repair and recovery.
Allogeneic multi-protein therapeutic (C-1101)
A donor-derived multi-protein biologic formulation composed of supraphysiologic concentrations of plasma- and platelet-derived cytokines, matrix proteins, and growth factors intended for local delivery to accelerate repair and recovery.
Expertise Areas
- Biologic therapeutic development
- Platelet- and plasma-derived therapeutics
- CMC and manufacturing scale-up
- Preclinical pharmacology and safety
Key Technologies
- Allogeneic multi-protein formulations
- Platelet/plasma-derived protein processing
- Biologics unit operations for protein therapeutics
- Aseptic filling and single-dose vial drug-product manufacturing
News & Updates
The company anticipates submitting an IND in Q2 2025 and initiating a Phase 1 clinical study in patients with chronic lumbosacral radiculopathy.
The company anticipates submitting an IND in Q2 2025 and initiating a Phase 1 clinical study in patients with chronic lumbosacral radiculopathy.